Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 8, 2016

View Archived Issues

Mitsubishi Tanabe profiles pipeline progress of second quarter of fiscal 2016

Lundbeck updates key developments of third quarter 2016

AZD-8931 does not improve progression-free survival in wild-type colorectal cancer patients

NIH award supports TherapyX's testing of IL10-NanoCap

NICE recommends Eisai's eribulin for breast cancer

Ascend Biopharmaceuticals reports interim results of phase I/IIa study on ASN-002

Study finds pharmacokinetic equivalence between Neulasta pegfilgrastim and Mylan/Biocon biosimilar

FDA accepts BLA for human rabies immunoglobulin

First-in-human study of Mucosis' SynGEM begins

GeoVax and ViaMune to codevelop cancer immunotherapy program

The Medicines Company discontinues development of MDCO-216

Amgen presents pipeline highlights of third quarter 2016

Vertex Pharmaceuticals reports positive phase III results on Orkambi

CHERISH study of Spinraza in later-onset SMA meets primary endpoint

TGFB1 may be behind coronary artery disease with glatiramer acetate treatment

FDA grants several orphan drug designations to APX-001

Scientists develop a new animal model for BBSOAS

H. Lundbeck patents PDE1 inhibitors

Guangdong Zhongsheng Pharmaceutical describes thromboxane synthase inhibitors

Guangzhou Maxinovel Pharmaceuticals develops ALK tyrosine kinase receptor inhibitors

Shire offers overview of third quarter 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...